Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx NextG UCITS ETF 04.11.2026 NXTG.LN IE00BWTNM743  170,002.00 USD   9,001,916.76   52.952  ...

NEW YORK--(BUSINESS WIRE)--DualEntry, the agentic ERP, is making the case for a new enterprise software model where businesses would pay for work completed by AI agents rather than simply for the number of employees accessing an application.The shift, described as Agents as a Service (AaaS), challenges the per-seat pricing model that has defined much of enterprise software for the past two decades. While traditional ERP systems provide the tools finance teams use to perform accounting work, AI a...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones International Internet UCITS ETF 04.11.2026 FDNI.LN IE00BT9PVG14  425,002.00 USD   7,294,035.93   17.162  ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the pricing of an underwritten offering of 10,235,077 shares of its common stock at a price of $7.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its common stock...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 04.11.2026 UIGB IE00079WNSI6   42,493.00 GBP   1,256,620.73   29.572  ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2026 results and recent business performance update. “Ironwood delivered a third consecutive strong quarter as we continue focused execution of our three strategic priorities: maximize LINZESS, advance apraglutide and deliver sustained profits and cas...

SCHAFFHAUSEN, Switzerland--(BUSINESS WIRE)--Versigent PLC (NYSE: VGNT), a global leader in the design and manufacture of low- and high-voltage electrical architectures, today announced Chief Financial Officer, Doug Ostermann, will participate in a fireside chat at the RBC Capital Markets Global Industrials Conference on Tuesday, November 17, 2026 at 10:40 a.m. ET. The live webcast will be available at the following link: https://kvgo.com/2026-global-Industrials-conference/versigent-plc-november...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 04.11.2026 UNCU.LN IE00BD6GCF16 1,069,907.00 USD  56,611,837.43   52.913  ...

RICHARDSON, Texas--(BUSINESS WIRE)--Vistance Networks, Inc. (NASDAQ: VISN) today announced Chuck Treadway will step down as President and CEO of the Company on February 1, 2027....

PITTSBURGH & LEEDS, United Kingdom--(BUSINESS WIRE)--Peptilogics, a clinical stage biotech company dedicated to curing and preventing medical device-related infections (MDRI), today announced that the first patient has been enrolled in the U.K. at Leeds Teaching Hospitals NHS Trust and NIHR Clinical Research Facility: Leeds, in the pivotal RETAIN Phase 2/3 trial of zaloganan (PLG0206) for treatment of prosthetic joint infection (PJI). Led by Investigators Dr. Hemant Pandit, Professor of Orthopa...